Envita's Biologics Laboratory and Cellular Division facility

Step into the forefront of cutting-edge medical innovation at Envita's Biologics Laboratory and Cellular Division facility. Since our establishment in 2001, our relentless team of physicians and scientists has been unwavering in its dedication to pioneering integrative cellular therapies for individuals grappling with cancer.

Through the years, our strides in Autologous Adoptive Immunotherapy (AAIT) biologic therapies have redefined personalized cancer immunotherapy for our patients. Fueled by a profound commitment to enhancing outcomes, our journey continues to push the boundaries of medical possibility. Welcome to a place where innovation meets compassion, and where the future of cancer care is being shaped today.

Immunotherapeutic breakthroughs have revolutionized cancer treatment, strategically aiming to amplify anti-tumor immune responses for the targeted recognition and eradication of cancer cells. Recent revelations about the suppressive impact of the tumor microenvironment (TME) on immune cells underscore the imperative to counteract these suppressive effects to achieve potent immunotherapy outcomes.

In the arsenal of cell types administered to cancer patients, Natural Killer (NK) cells emerge as powerful agents, directly eliminating tumor cells through the deployment of cytotoxic granzymes. Dendritic cells (DCs), with their pivotal role in presenting antigens and instigating tumor-antigen specific CD8+ T cell responses, are harnessed to intensify anti-tumor immunity. Particularly, DCs specializing in cross-presenting extracellular antigens to CD8+ T cells exhibit great promise in the landscape of cancer treatment.

Within the intricate landscape of the TME, DCs engage in dynamic communication with NK cells, fostering heightened recruitment, differentiation, maturation, activation, and stimulation of NK cells. As a result, the concerted presence of DCs and NK cells within the TME emerges as critical factors for successful cancer immunotherapeutic treatment.

Welcome to AAIT, Autologous Adoptive Immunotherapy, where highly targeted NK cells and DCs developed over 2 decades helps patients that are candidates for cancer immunotherapy treatment.

NK cells play a crucial role in adoptive immunotherapy by targeting and destroying tumor cells without prior sensitization. Their activation occurs upon encountering tumor cells through specific receptor binding, leading to various elimination methods like perforin and granzyme release, ADCC, and induction of cytotoxicity via apoptotic pathways.

Clinical studies underscore the potential of NK cell-based immunotherapy in cancer treatment. Overcoming inhibited NK cell function in cancer patients is achieved through adoptive immunotherapy with expanded and activated NK cells. Envita's proprietary Ex vivo expansion and activation has been developed over 2 decades with focus on safety and effective expansion to increase both the number and antitumor activity of NK cells, effectively addressing immunosuppression prevalent in solid tumors.

Select cytokines, peptides specialized culture techniques are employed to generate robust NK cells for adoptive immunotherapy. These methods have been constantly improved over 2 decades with our team of physicians and scientists to contribute to enhanced NK cell proliferation, activation, cytotoxicity and conditioning for effective targeting of resistant cancer cells and tumors.

Dendritic cells (DCs) are specialized immune cells that play a crucial role in eliciting immune responses, particularly against tumor antigens in cancer therapy. They emerge as significant targets for therapeutic interventions in cancer.

Ex vivo stimulation of DCs with pro-inflammatory molecules and their loading with tumor-specific antigen(s) form the basis of various protocols for DCs vaccination manufacturing. While specific details of these protocols may vary, the safety of DCs vaccination and its capacity to induce antitumor responses are consistently established. Extensive research spanning many years has concentrated on the potential of DCs to enhance overall survival, particularly in a subset of cancer patients.

Insights gained from early trials have led to the hypothesis that, to optimize the efficacy of DCs-based immunotherapy, it should be integrated with other treatments. Consequently, the ultimate role of the vaccine may hinge on its integration into combinatorial approaches in the realm of DCs-based immunotherapy.

Pseudoprogression, a distinctive response to immunotherapy, presents a temporary appearance or a false rise in tumor burden or new lesions, succeeded by subsequent tumor regression. This phenomenon is attributed to the infiltration of immune cells surrounding a tumor prompted by immunotherapy treatment.

Although imaging may indicate an apparent increase in tumor size, it is crucial to recognize that this perception may arise from the simultaneous visualization of both the tumor and the surrounding immune cells. In instances where new metastases manifest during pseudoprogression, often small pre-existing metastases (micrometastases) were already present before initiating immunotherapy but unable to be visualized in prior imaging.

However, due to the influx of surrounding immune cells, these metastases become visible on imaging studies. Understanding and interpreting pseudoprogression is paramount, as it signifies a positive response to AAIT treatment, highlighting the intricate interplay between immunotherapy and the body's immune system in combating cancer.